R&D consulting with a difference
TherapeutAix is a life sciences consultancy company with a global client base.
TherapeutAix combines strategy and subject matter expertise with a fully integrated R&D network to deliver practical, cost and time efficient solutions for your project.
We are experts in pre-clinical, translational and clinical drug discovery with a strong background in the pharmaceutical industry.
Every project is unique. That is why we offer bespoke solutions, ranging from advice all the way to project management and operationalisation.
We offer an initial review of your project completely free of charge. This allows us to assess the project and see how we can work together.
Find out more about how we work.
About TherapeutAix
Learn more about what we do, what areas we have expertise in, and how we work with you towards success.
What We Do
At TherapeutAix we are a passionate group of scientists with a strong background of experience in the pharmaceutical industry.
Our goal is to ultimately help more medicines reach patients.
Our Therapeutic Areas
Collectively, the TherapeutAix team has a successful track record in the cardiovascular, inflammation, immunology, neuroscience, respiratory, pain, tissue repair and urology.
How We Work
We like to think of ourselves as part of your team, working towards a common goal together. We can assist your project as the people you need in the places where you need us, guiding you along the way.
Latest updates
The latest news and blogs from the TherapeutAix team. To see more, visit our news page here.
TherapeutAix Roundup: 2024
As another year comes to a close, we reflect on 12 months filled with innovation and collaboration at TherapeutAix. From kickstarting the year with strategic
Exploring the Potential of Inhalation Therapies for IPF: Lessons from Asthma
A few weeks ago, our updated review on the state of drug development in Idiopathic Pulmonary Fibrosis (IPF) was published in Drug Discovery Today. This update
The Evolving Landscape of IPF Drug Discovery and Development
Idiopathic Pulmonary Fibrosis (IPF) remains one of the most challenging respiratory diseases to treat, characterized by progressive lung scarring and severely unpredictable disease progression. Despite
TherapeutAix to attend ERS Congress 2024
TherapeutAix will be at the ERS Congress 2024 taking place in Vienna, Austria from 7-11th September. The Congress, hosted at RX Messe Wien, will bring